&lt;i&gt;Interleukin-18&lt;/i&gt; Promoter Polymorphism and Development of Antibodies to Surface Antigen of Hepatitis B Virus in Hemodialysis Patients

Grzegorzewska, Alicja E.; Wobszal, Piotr; Jagodzińśki, Paweł P.

doi:10.1159/000329932

Cited by 14 publications

(12 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that effective seroconversion after vaccination of HD patients depends on age, body mass, serum albumin concentration, type of dialyzer, duration of RRT, and underlying kidney disease [18,32-36]. Such risk factors of non-responsiveness as older age, shorter RRT duration and diabetic nephropathy were also present in the examined non-responders compared to responders.…”

Section: Discussionmentioning

confidence: 99%

“…More recently, IL genotypes ( IL10 IL-18 ) were associated with anti-HBs development in response to HBsAg in HD patients [18,39]. …”

Section: Discussionmentioning

confidence: 99%

“…In other studies using IL12 p40 −/− or IL18 −/− mice, only IL-12 p40 or IL-18 was important for defense against human viruses adapted to the mouse [15,16]. In HD patients, the IL18 -1297CC rs360719 genotype, attributed to increased IL-18 secretion [17], was recently connected with the development of anti-HBs [18]. It is not known whether the IL12 genotype is concomitantly associated with the IL18 genotype in the development of anti-HBs.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients

et al. 2012

View full text Add to dashboard Cite

BackgroundThe interleukin (IL)18 rs360719 CC genotype is associated with the development of antibodies to hepatitis B virus surface antigen (anti-HBs) in hemodialysis (HD) patients. IL18 shares biological properties with IL12 in promoting the T-hepler 1 (Th1) system. We studied whether polymorphisms in the IL12A 3` untranslated region (UTR) and IL12B 3`UTR may contribute to anti-HBs development (titre ≥ 10 IU/L) in HD patients either individually or jointly with the IL18 polymorphism.MethodsIn 518 HD patients and 240 controls the IL12A rs568408 3’UTR G > A polymorphism was genotyped by high-resolution melting curve analysis. Polymerase chain reaction restriction fragment length polymorphism was used to detect the IL12B rs3212227 3’UTR A > C and IL18 -1297 T > C rs360719 polymorphisms. The associations between the IL12A, IL12B and IL18 genotypes and the risk of impaired anti-HBs development were estimated by computing the odds ratios and their 95% confidence intervals using logistic regression analysis.ResultsIn the logistic regression analysis, the higher frequency of rs360719 CC individually (2.9% in 207 patients without anti-HBs development vs 8.0% in 311 patients with anti-HBs development, p = 0.009) and of rs360719 CC combined with rs568408 GG (p = 0.048), rs568408 GA (p = 0.035), rs568408 GG/AA (p = 0.034) or rs3212227 AA (p = 0.046) was associated with an increased chance for the development of anti-HBs in HD patients. Patients bearing both rs568408 AA and rs360719 TT had a 10.9-fold or 8.9-fold lower chance, respectively, to develop anti-HBs compared with those carrying any other genotype (p = 0.005) or those who had both wild-type rs568408 GG and rs360719 TT (p = 0.011). Carriers of both rs3212227 CC and rs360719 TC had a 4.6-fold lower chance for anti-HBs development than carriers of any other genotype (p = 0.042).ConclusionDevelopment of anti-HBs in HD patients is associated with gene polymorphisms of interleukins involved in the Th1 system.

show abstract

Section: Discussionmentioning

confidence: 99%

“…More recently, IL genotypes ( IL10 IL-18 ) were associated with anti-HBs development in response to HBsAg in HD patients [18,39]. …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Genes encoding IL-18 (IL18 rs360719) and IL-12B p40 (IL12B rs321227) were linked to the development of anti-HBs in HD patients. 27, 28 On the other hand, the monocyte chemotactic protein 1 gene (MCP1-2518 A/G rs1024611) was not associated with anti-HBs formation in response to HBV vaccination, 29 although MCP1 is involved in Th2 polarization. 30 Secondly, our study was conducted in patients on RRT, who have impaired immune response.…”

Section: Massachusettsmentioning

confidence: 99%

Effect of interferon λ3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients

Grzegorzewska¹,

Jodłowska²,

Mostowska³

et al. 2015

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

IntroductIon The higher prevalence and risk of hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are still observed in hemodialysis (HD) patients compared with healthy people. Interferons (IFNs) are known for their involvement in immune response. The addition of IFN-λ3 to immunization in animal models was shown to increase the immune response of T helper-1 cells.objectIves We studied whether polymorphisms of the IFN-λ3 gene (IFNL3) might be associated with the development of antibodies to HBV surface antigen [anti-HBs] in response to the HBV vaccination or HBV infection as well as spontaneous resolution of HCV infection in HD patients. PAtIents And methodsThe HD group consisted of 806 individuals without a history of HBV or HCV infection (of whom 672 developed anti-HBs in response to the HBV vaccination), 241 HBV-infected patients (of whom 186 developed anti-HBs), and 63 HCV-infected patients (including 39 HCV RNA-positive subjects). All patients were genotyped for IFNL3 rs8099917 and rs12979860 polymorphisms using a high-resolution melting curve analysis.results The comparison of responders and nonresponders to HBV vaccination revealed no significant differences in the IFNL3 genotype distribution. In HBV-infected patients, the differences in the distribution of IFNL3 variants between anti-HBs-negative and anti-HBs-positive patients were also nonsignificant. Spontaneous HCV clearance was significantly less common in the carriers of the rs8099917 allele G or rs12979860 allele T, while the CT rs12979860_rs8099917 haplotype was more frequent (P = 0.02) in patients showing spontaneous HCV clearance.conclusIons In HD patients, the IFNL3 polymorphisms do not affect anti-HBs development in response to HBV infection or vaccination, but might be involved in the resolution of HCV infection. 895uremic conditions. Therefore, we aimed to show whether the SNPs of IFNL3 might be associated with the development of antibodies to HBV surface antigen (anti-HBs) in response to HBV vaccination or infection as well as with spontaneous HCV clearance in HD patients. PAtIents And methods Patients and controlsThe study included 1110 patients on renal replacement therapy (RRT). They were recruited from 21 dialysis centers located in the Greater Poland region of Poland. The enrollment was started in January, 2009, and finished in May, 2014. All patients were treated with HD on enrollment; however, 28 subjects (2.5%) started RRT with peritoneal dialysis. Subjects dually infected with HBV and HCV or those infected with human immunodeficiency virus were excluded from the study. Of the whole group, 63 patients were HCV-infected (showed antibodies to HCV, anti-HCV) but only 39 of the 63 showed positive for HCV RNA. The remaining 1047 patients were anti-HCV negative, of whom 806 had no history of HBV infection, while 241 were HBV-infected (showed total antibodies to the core antigen of HBV, anti-HBc). In the latter group, 186 subjects developed anti-HBs. HD patient groups are shown in FIGure 1.Subjects were included into th...

show abstract

“…Results of these studies indicate that in renal replacement therapy (RRT) subjects, there is a relatively weak association between polymorphisms of genes encoding Th cell cytokines and development of antibodies to surface antigen of hepatitis B virus (anti-HBs) in response to hepatitis B vaccination or hepatitis B virus (HBV) infection. [25][26][27][28][29][30] Active immunization against HBV may be less effective in ESRD patients due to vitamin D deficiency. 31 Vitamin D related genetic background may contribute to lower response to hepatitis B vaccination.…”

Section: Vaccination Against Hepatitis B Virusmentioning

confidence: 99%

Prophylactic vaccinations in chronic kidney disease: Current status

Grzegorzewska¹

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

<i>Interleukin-18</i> Promoter Polymorphism and Development of Antibodies to Surface Antigen of Hepatitis B Virus in Hemodialysis Patients

Cited by 14 publications

References 56 publications

Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients

Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients

Effect of interferon λ3 gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients

Prophylactic vaccinations in chronic kidney disease: Current status

Contact Info

Product

Resources

About